Pancreatic Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PNC129 MIFTS: 65	Pancreatic Adenocarcinoma Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pancreatic Adenocarcinoma

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma ¹¹ ²⁸ ⁵ ¹⁴ ¹⁶ ³³

Adenocarcinoma of Pancreas ⁷¹ ³³

Mixed Adenocarcinoma Islet Cell with Exocrine of Unspecified Site ³³

Islet Cell Adenocarcinoma of Unspecified Site ³³

Adenocarcinoma of Islet Cell of Pancreas ³³

Primary Pancreatic Adenocarcinoma ³³

Adenocarcinoma of the Pancreas ¹¹

Malignant Exocrine Neoplasm ³³

Pancreas Adenocarcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasm of pancreas

Adenocarcinoma of pancreas

External Ids:

Disease Ontology ¹¹ DOID:4074

NCIt ⁴⁹ C8294

SNOMED-CT ⁶⁸ 700423003

EFO ¹⁶ EFO_1000044

ICD11 ³³ 1663659989

UMLS ⁷¹ C0281361

Sources

Summaries for Pancreatic Adenocarcinoma

Disease Ontology: ¹¹ A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Pancreatic Adenocarcinoma, also known as adenocarcinoma of pancreas, is related to pancreatic ductal adenocarcinoma and adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Propofol and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include pancreas, t cells and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Pancreatic Adenocarcinoma

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)

#	Related Disease	Score	Top Affiliating Genes
1	pancreatic ductal adenocarcinoma	32.5	U2AF1 TP53 SMAD4 KRAS HRAS
2	adenocarcinoma	32.3	TP53 SMAD4 PIK3CA MUC4 KRAS HRAS
3	pancreatic acinar cell adenocarcinoma	32.2	SMAD4 KRAS HRAS
4	pancreatic cancer	31.6	TP53 SMAD4 PIK3CA MUC4 MAP2K2 KRAS
5	exanthem	31.2	KRAS HRAS ERBB2 EGFR
6	inherited cancer-predisposing syndrome	31.0	TP53 SMAD4 POLE EGFR CDKN2A
7	bap1 tumor predisposition syndrome	31.0	TP53 SMAD4 POLE EGFR CDKN2A
8	papilloma	31.0	TP53 KRAS ERBB2 EGFR CDKN2A
9	breast ductal carcinoma	30.9	TP53 SMAD4 ERBB2 EGFR CTNNB1
10	ampulla of vater adenocarcinoma	30.9	SMAD4 KRAS HRAS
11	cholecystitis	30.8	TP53 MUC4 EGFR CDKN2A
12	appendix adenocarcinoma	30.8	TP53 SMAD4 KRAS HRAS GNAS
13	cholangiocarcinoma	30.8	TP53 SMAD4 PIK3CA MUC4 KRAS ERBB2
14	biliary tract cancer	30.7	TP53 SMAD4 MUC4 ERBB2 EGFR
15	pancreatic ductal carcinoma	30.7	TP53 SMAD4 KRAS HRAS ERBB2 EGFR
16	pancreatoblastoma	30.7	SMAD4 KRAS HRAS CTNNB1 CDKN2A
17	peutz-jeghers syndrome	30.6	TP53 SMAD4 GNAS EGFR CTNNB1
18	cervical adenocarcinoma	30.6	TP53 KRAS CDKN2A
19	adenosquamous carcinoma	30.5	MUC4 KRAS HRAS EGFR
20	neurofibromatosis	30.5	TP53 KRAS HRAS EGFR CDKN2A
21	klatskin's tumor	30.5	TP53 KRAS HRAS
22	gastroesophageal junction adenocarcinoma	30.5	TP53 ERBB2 EGFR
23	gastric cancer	30.4	TP53 SMAD4 PIK3CA MUC4 KRAS ERBB2
24	hemangioma	30.4	TP53 KRAS EGFR CTNNB1 CDKN2A
25	adenocarcinoma in situ	30.4	U2AF1 TP53 KRAS HRAS EGFR CDKN2A
26	ampulla of vater cancer	30.4	TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
27	laryngeal squamous cell carcinoma	30.4	TP53 ERBB2 EGFR CDKN2A
28	pseudomyxoma peritonei	30.3	TP53 KRAS GNAS CTNNB1
29	low grade glioma	30.3	TP53 EGFR CDKN2A
30	hereditary breast ovarian cancer syndrome	30.3	TP53 SMAD4 POLE PIK3CA KRAS HRAS
31	vaginal cancer	30.3	TP53 HRAS EGFR CDKN2A
32	duodenum adenocarcinoma	30.3	SMAD4 KRAS HRAS
33	duodenum cancer	30.3	TP53 SMAD4 KRAS HRAS ERBB2
34	diffuse gastric cancer	30.3	TP53 SMAD4 PIK3CA KRAS ERBB2 CTNNB1
35	cervical squamous cell carcinoma	30.3	TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
36	papillary adenocarcinoma	30.3	TP53 KRAS HRAS ERBB2
37	signet ring cell adenocarcinoma	30.3	TP53 KRAS HRAS ERBB2 CTNNB1
38	mucinous cystadenocarcinoma	30.3	SMAD4 KRAS HRAS
39	keratosis, seborrheic	30.3	TP53 PIK3CA CDKN2A
40	familial adenomatous polyposis	30.3	TP53 SMAD4 KRAS HRAS CTNNB1
41	brain glioma	30.2	U2AF1 TP53 ERBB2 EGFR CDKN2A
42	gallbladder disease	30.2	TP53 KRAS HRAS ERBB2 EGFR CTNNB1
43	esophagus adenocarcinoma	30.2	TP53 ERBB2 EGFR CTNNB1 CDKN2A
44	colonic benign neoplasm	30.2	TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
45	mantle cell lymphoma	30.2	U2AF1 TP53 ERBB2 EGFR CDKN2A
46	rectum cancer	30.2	TP53 KRAS HRAS EGFR
47	malignant pleural mesothelioma	30.2	TP53 HRAS EGFR CDKN2A
48	teratoma	30.2	TP53 KRAS ERBB2 CTNNB1 CDKN2A
49	barrett esophagus	30.2	TP53 SMAD4 ERBB2 CTNNB1 CDKN2A
50	suppressor of tumorigenicity 3	30.2	TP53 CDKN2A

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:

Sources

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

UMLS symptoms related to Pancreatic Adenocarcinoma:

abdominal pain; pruritus; icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show top 50) (show all 55)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.74	EGFR HRAS KRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.74	EGFR HRAS KRAS PIK3CA
3	Decreased viability	GR00055-A-3	10.74	KRAS
4	Decreased viability	GR00106-A-0	10.74	KRAS
5	Decreased viability	GR00221-A-1	10.74	EGFR HRAS KRAS PIK3CA CDKN2A RXRA
6	Decreased viability	GR00221-A-2	10.74	HRAS KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.74	HRAS CDKN2A
8	Decreased viability	GR00221-A-4	10.74	EGFR PIK3CA CDKN2A
9	Decreased viability	GR00249-S	10.74	RXRA
10	Decreased viability	GR00301-A	10.74	KRAS
11	Decreased viability	GR00381-A-1	10.74	KRAS RXRA
12	Decreased viability	GR00402-S-2	10.74	PIK3CA
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-104	10.55	MED12
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-108	10.55	MED12
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-109	10.55	MYCN
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	10.55	MED12
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	10.55	TP53
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.55	TP53 KRAS U2AF1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.55	EGFR
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	10.55	TP53
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-136	10.55	U2AF1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-138	10.55	MYCN
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	10.55	MED12 U2AF1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-165	10.55	MYCN
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	10.55	TP53
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-173	10.55	MYCN
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.55	MYCN
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-184	10.55	TP53
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	10.55	MED12
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	10.55	TP53
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.55	MED12 TP53
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-20	10.55	TP53
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.55	EGFR
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	10.55	U2AF1
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.55	EGFR
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	10.55	KRAS
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-23	10.55	MED12
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-26	10.55	MED12
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-34	10.55	MED12
40	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	10.55	TP53
41	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	10.55	TP53
42	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.55	EGFR
43	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	10.55	CTNNB1
44	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	10.55	PIK3CA
45	Increased shRNA abundance (Z-score > 2)	GR00366-A-62	10.55	TP53
46	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.55	KRAS
47	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	10.55	MED12
48	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.55	EGFR U2AF1
49	Increased shRNA abundance (Z-score > 2)	GR00366-A-89	10.55	MED12 U2AF1
50	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	10.55	MED12

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

⁴⁵ (show all 27)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.5	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2	homeostasis/metabolism	MP:0005376	10.48	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
3	growth/size/body region	MP:0005378	10.46	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
4	nervous system	MP:0003631	10.42	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
5	normal	MP:0002873	10.4	CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
6	muscle	MP:0005369	10.38	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
7	cardiovascular system	MP:0005385	10.38	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
8	digestive/alimentary	MP:0005381	10.37	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
9	endocrine/exocrine gland	MP:0005379	10.33	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
10	embryo	MP:0005380	10.31	CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
11	cellular	MP:0005384	10.31	CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
12	craniofacial	MP:0005382	10.29	CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
13	limbs/digits/tail	MP:0005371	10.28	CTNNB1 EGFR ERBB2 GNAS KRAS MED12
14	no phenotypic analysis	MP:0003012	10.27	CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
15	behavior/neurological	MP:0005386	10.27	CDKN2A CTNNB1 ERBB2 GNAS HRAS KRAS
16	renal/urinary system	MP:0005367	10.26	CTNNB1 EGFR GNAS HRAS KRAS MYCN
17	immune system	MP:0005387	10.25	CDKN2A CTNNB1 EGFR GNAS KRAS LRRC56
18	liver/biliary system	MP:0005370	10.24	CDKN2A CTNNB1 EGFR GNAS KRAS MYCN
19	pigmentation	MP:0001186	10.18	CDKN2A CTNNB1 EGFR KRAS RXRA TP53
20	respiratory system	MP:0005388	10.18	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
21	hearing/vestibular/ear	MP:0005377	10.17	CTNNB1 EGFR GNAS KRAS MAP2K2 RXRA
22	skeleton	MP:0005390	10.17	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
23	reproductive system	MP:0005389	10.15	CDKN2A CTNNB1 EGFR ERBB2 KRAS LRRC56
24	vision/eye	MP:0005391	10	CDKN2A CTNNB1 EGFR GNAS KRAS MAP2K2
25	hematopoietic system	MP:0005397	9.93	CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
26	mortality/aging	MP:0010768	9.91	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
27	integument	MP:0010771	9.5	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS

Sources

Drugs & Therapeutics for Pancreatic Adenocarcinoma

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Desflurane

Approved

Phase 4

57041-67-5

42113

Anesthetics, Inhalation

Phase 4

Anesthetics, General

Phase 4

Darbepoetin alfa

Approved, Investigational

Phase 2, Phase 3

209810-58-2

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Epirubicin

Approved

Phase 2, Phase 3

56420-45-2

41867

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Phenytoin

Approved, Vet_approved

Phase 3

57-41-0

1775

Methoxsalen

Approved

Phase 3

298-81-7

4114

Olaparib

Approved

Phase 3

763113-22-0

23725625

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Asparagine

Approved, Investigational, Nutraceutical

Phase 3

70-47-3

6267

Irofulven

Investigational

Phase 3

158440-71-2

3844471 148189

Chrysarobin

Phase 2, Phase 3

Hematinics

Phase 3

ON 01910

Phase 3

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3

topoisomerase I inhibitors

Phase 3

Calcium, Dietary

Phase 3

Pharmaceutical Solutions

Phase 3

Endothelial Growth Factors

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 2

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 2

9041-08-1

Sargramostim

Approved, Investigational

Phase 1, Phase 2

123774-72-1

Dipyridamole

Approved

Phase 2

58-32-2

3108

Etanercept

Approved, Investigational

Phase 1, Phase 2

185243-69-0

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Cobalt

Approved, Experimental, Withdrawn

Phase 2

7440-48-4

104729

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

Interventional clinical trials:

(show top 50) (show all 741)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer	Unknown status	NCT03401827	Phase 4	Chemotherapy (Gemcitabine + nab-paclitaxel)
2	A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma	Completed	NCT00854477	Phase 4	capecitabine
3	Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?	Completed	NCT02335151	Phase 4	Desflurane
4	Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study	Completed	NCT00578279	Phase 4	dehydrated alcohol
5	A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma	Withdrawn	NCT03891979	Phase 4	Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
6	Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy	Withdrawn	NCT01401387	Phase 4
7	Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Unknown status	NCT02072616	Phase 3
8	Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma	Unknown status	NCT01065870	Phase 2, Phase 3	Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
9	A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)	Unknown status	NCT01077427	Phase 3	Gemcitabine + Capecitabine
10	A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen	Unknown status	NCT00088660	Phase 3
11	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	Completed	NCT02993731	Phase 3	Napabucasin;Nab-paclitaxel;Gemcitabine
12	Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma	Completed	NCT03673137	Phase 2, Phase 3	Gemcitabine
13	A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma	Completed	NCT01964430	Phase 3	nab-Paclitaxel;Gemcitabine
14	Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma	Completed	NCT00033735	Phase 3	fluorouracil;Irofulven
15	A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine	Completed	NCT00099294	Phase 3	Glufosfamide
16	Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil	Completed	NCT00960284	Phase 2, Phase 3	capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
17	A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma	Completed	NCT03665441	Phase 3	eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
18	A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma	Completed	NCT02436668	Phase 3	Ibrutinib;Gemcitabine;Nab-paclitaxel
19	A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma	Completed	NCT00003216	Phase 3	fluorouracil;gemcitabine hydrochloride
20	Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma	Completed	NCT01526135	Phase 3	mFolfirinox;Gemcitabine
21	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	Completed	NCT01746979	Phase 3	TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
22	A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment	Completed	NCT03126435	Phase 3	EndoTAG-1;Gemcitabine
23	A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma	Completed	NCT03943667	Phase 3	Gemcitabine;Paclitaxel
24	A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer	Completed	NCT01360853	Phase 3	ON 01910.Na;Gemcitabine
25	A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer	Completed	NCT00088894	Phase 3	gemcitabine hydrochloride
26	A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas	Completed	NCT00844649	Phase 3	Albumin-bound paclitaxel (ABI-007);Gemcitabine
27	Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study	Completed	NCT00634725	Phase 3	capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
28	Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4)	Completed	NCT00044031	Phase 3
29	A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas	Completed	NCT03504423	Phase 3	CPI 613, mFolfirinox;Folfirinox
30	A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine	Recruiting	NCT01954992	Phase 3	Glufosfamide;Fluorouracil
31	A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma	Recruiting	NCT03899636	Phase 3	Modified FOLFIRINOX Regimen
32	Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX	Recruiting	NCT04167007	Phase 3	Gemcitabine;FOLFOX
33	Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma	Recruiting	NCT03377491	Phase 3	Gemcitabine;nab paclitaxel
34	A Phase Ⅲ, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer	Recruiting	NCT04617821	Phase 3	Nab paclitaxel plus gemcitabine;mFOLFIRINOX
35	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Recruiting	NCT04340141	Phase 3	Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
36	Precision Promise Platform Trial for Metastatic Pancreatic Cancer	Recruiting	NCT04229004	Phase 3	Gemcitabine combined with nab-paclitaxel;Dose -mFOLFIRINOX;Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel;Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine;Drug: Dose -SM-88
37	Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study	Recruiting	NCT04927780	Phase 3	Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Oxaliplatin
38	Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP	Recruiting	NCT05268692	Phase 2, Phase 3	GS;GnP
39	Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors	Recruiting	NCT05181605	Phase 2, Phase 3	Folfirinox and Stereotactic Body Radiotherapy
40	Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis	Recruiting	NCT03251365	Phase 2, Phase 3	HIPEC-gemcitabine
41	An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas	Active, not recruiting	NCT04083235	Phase 3	Irinotecan Liposomal Injection;Oxaliplatin;5Fluorouracil;Leucovorin;Nab-paclitaxel;Gemcitabine
42	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	Active, not recruiting	NCT02184195	Phase 3	Olaparib;Placebo
43	A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma	Active, not recruiting	NCT01013649	Phase 3	Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
44	A Phase III, Multicenter, Prospective, Randomized, Patients With Resectable Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.	Not yet recruiting	NCT04835064	Phase 3	Nab paclitaxel;Gemcitabine;mFOLFIRINOX
45	Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease	Not yet recruiting	NCT05482516	Phase 3	Atezolizumab;Bevacizumab
46	Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma	Terminated	NCT01900327	Phase 3	Gemcitabine neoadjuvant;Gemcitabine adjuvant
47	An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)	Terminated	NCT01956812	Phase 3	IMMU-107;placebo;Gemcitabine
48	Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial	Terminated	NCT01419002	Phase 3
49	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas	Terminated	NCT01231347	Phase 3	AMG 479;Placebo;gemcitabine
50	A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)	Terminated	NCT02119663	Phase 3	Ruxolitinib;Placebo;Capecitabine

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Sources

Genetic Tests for Pancreatic Adenocarcinoma

Genetic tests related to Pancreatic Adenocarcinoma:

#	Genetic test	Affiliating Genes
1	Pancreatic Adenocarcinoma ²⁸

Sources

Anatomical Context for Pancreatic Adenocarcinoma

Organs/tissues related to Pancreatic Adenocarcinoma:

MalaCards : Pancreas, T Cells, Lymph Node, Endothelial, Lung, Liver, Colon

Sources

Publications for Pancreatic Adenocarcinoma

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 9752)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. ⁶²	Rossi G...Arcidiacono PG	35898840	2023
3	Distal cholangiocarcinoma: case report and brief review of the literature. ⁶²	Hathaway QA...Kim C	36444360	2023
4	Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. ⁶²	Zhang M...Li Q	36416310	2023
5	Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer. ⁶²	Kalagara R...Wasif N	36102533	2022
6	Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. ⁶²	Kemp Bohan PM...Nelson DW	36460898	2022
7	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. ⁶²	Kindler HL...Golan T	35834777	2022
8	Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. ⁶²	Brugel M...Bouche O	36089524	2022
9	YAP activates pancreatic stellate cells and enhances pancreatic fibrosis. ⁶²	Spanehl L...Jaster R	35753954	2022
10	Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma. ⁶²	Mafficini A...Luchini C	36056133	2022
11	Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. ⁶²	Neuzillet C...Bousquet C	36102377	2022
12	Screening of an annexin-A2-targeted heptapeptide for pancreatic adenocarcinoma localization. ⁶²	Ma H...Wei M	36453020	2022
13	Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. ⁶²	Sardar M...Babiker H	36394449	2022
14	X-linked inhibitor of apoptosis protein is a prognostic marker for a favorable outcome in three identified subsets in resectable adenocarcinoma of the pancreas. ⁶²	Knipper K...PANCALYZE Study Group	36472768	2022
15	Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma? ⁶²	Anger F...Lob S	36094690	2022
16	Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review. ⁶²	Alexander HC...Bartlett ASJR	36084842	2022
17	Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. ⁶²	Temraz S...Shamseddine A	35362216	2022
18	Role of biliary drainage before pancreatoduodenectomy for pancreatic adenocarcinoma: a retrospective study. ⁶²	Scherber PR...Glanemann M	35230040	2022
19	Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma. ⁶²	Li Q...Yang X	35902397	2022
20	A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. ⁶²	Heumann TR...Azad NS	36463226	2022
21	Systematic analysis of expression profiles and prognostic significance of the FGF gene family in pancreatic adenocarcinoma. ⁶²	Chen YX...Mai J	36311692	2022
22	Role of Up-Regulated Transmembrane Channel-Like Protein 5 in Pancreatic Adenocarcinoma. ⁶²	Gan XY...Wei DM	36459296	2022
23	Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). ⁶²	Yang Y...Qiu Z	36328194	2022
24	NDUFA4 promotes cell proliferation by enhancing oxidative phosphorylation in pancreatic adenocarcinoma. ⁶²	Zhang Y...Wu X	36307669	2022
25	Feasibility and outcome of spleen and vessel preserving total pancreatectomy (SVPTP) in pancreatic malignancies - a retrospective cohort study. ⁶²	Beltzer C...Nadalin S	36169725	2022
26	Characterizing gastrointestinal dysfunction after pancreatic resection: a single-center retrospective study. ⁶²	Bromley-Dulfano R...Visser B	36435757	2022
27	High-risk liver patients are not associated with adverse events following pancreaticoduodenectomy. ⁶²	Mangieri CW...Clark CJ	36428108	2022
28	Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers. ⁶²	Fiore PF...Vacca P	36451048	2022
29	Assessment of spatial transcriptomics for oncology discovery. ⁶²	Lyubetskaya A...Drokhlyansky E	36452860	2022
30	A pan-cancer analysis of the oncogenic role of ATP binding cassette subfamily E member 1 (ABCE1) in human tumors: An observational study. ⁶²	Yu J...Dai Z	36401432	2022
31	Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature. ⁶²	Eckhoff AM...Allen PJ	35831529	2022
32	Evaluating the Impact of Preoperative Geriatric-Specific Variables and Modified Frailty Index on Postoperative Outcomes After Elective Pancreatic Surgery. ⁶²	Cramer CL...Zaydfudim VM	36076089	2022
33	Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells. ⁶²	Guler S...Yalcin A	36053282	2022
34	Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies. ⁶²	Elshami M...Ocuin LM	36402613	2022
35	Systematic review, meta-analysis and single-centre experience of the diagnostic accuracy of intraoperative near-infrared indocyanine green-fluorescence in detecting pancreatic tumours. ⁶²	Rompianesi G...Troisi RI	35654671	2022
36	Intramedullary pancreatic adenocarcinoma metastasis: The first case in literature. ⁶²	Tahta A...Dinc C	36333089	2022
37	A Novel Immune-Related Gene Prognostic Index (IRGPI) in Pancreatic Adenocarcinoma (PAAD) and Its Implications in the Tumor Microenvironment. ⁶²	Zhou S...Hajdu A	36428747	2022
38	Oncological management dilemma: a rare presentation of hairy cell leukaemia with hepatic involvement presenting concomitantly with pancreatic adenocarcinoma. ⁶²	Al-Saheli ZI...Barthel B	36414341	2022
39	Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma. ⁶²	Xu D...Shi Y	36401386	2022
40	Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. ⁶²	Kawakubo K...Liss AS	36048239	2022
41	A novel risk score model based on four angiogenesis long non-coding RNAs for prognosis evaluation of pancreatic adenocarcinoma. ⁶²	Cao G...Han K	36384673	2022
42	Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). ⁶²	Bryant JM...Frakes J	36420193	2022
43	A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. ⁶²	Saif A...Hall WA	36427115	2022
44	LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. ⁶²	Xu R...Shi C	36428619	2022
45	Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma. ⁶²	Li L...Liu R	36371178	2022
46	Prolonged complete response after neoadjuvant capecitabine-gemcitabine for a locally advanced pancreatic adenocarcinoma: A case report. ⁶²	Ekwunife CN...Iwuagwu OC	36412306	2022
47	Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. ⁶²	Kawakubo K...Liss AS	36114896	2022
48	Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma. ⁶²	Gong Q...Li Z	36408702	2022
49	KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6. ⁶²	Mi W...Li F	36438710	2022
50	Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. ⁶²	Roth GS...de la Fouchardiere C	36358831	2022

Sources

Genes for Pancreatic Adenocarcinoma

Genes related to Pancreatic Adenocarcinoma (0 elite genes):

(show top 50) (show all 82)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	59.37	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	26619011
2	SMAD4	SMAD Family Member 4	Protein Coding	58.55	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	26619011
3	TP53	Tumor Protein P53	Protein Coding	58.27	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	26619011
4	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	57.48	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	26619011
5	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	48.04	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	26619011
6	GNAS	GNAS Complex Locus	Protein Coding	38.16	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
7	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	38.14	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Pathways & Interactions (show sections)	26619011
8	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	36.18	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Pathways & Interactions (show sections)	26619011
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	34	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
10	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	33.82	Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴	26619011
11	CTNNB1	Catenin Beta 1	Protein Coding	32.64	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
12	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	30.5	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
13	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	29.97	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
14	RXRA	Retinoid X Receptor Alpha	Protein Coding	28.81	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
15	MED12	Mediator Complex Subunit 12	Protein Coding	28.5	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
16	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011
17	MYCNOS	MYCN Opposite Strand	RNA Gene	25	Likely pathogenic ⁵	26619011
18	SF3B2	Splicing Factor 3b Subunit 2	Protein Coding	25	Likely pathogenic ⁵	26619011
19	EGFR	Epidermal Growth Factor Receptor	Protein Coding	23.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
20	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	23.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)
21	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	23.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
22	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	23.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
23	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	22.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
24	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	22.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
25	EGF	Epidermal Growth Factor	Protein Coding	22.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
26	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	22.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
27	IL6	Interleukin 6	Protein Coding	22.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
28	CCND1	Cyclin D1	Protein Coding	22.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
29	CEACAM6	CEA Cell Adhesion Molecule 6	Protein Coding	22.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
30	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	22.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
31	MMP9	Matrix Metallopeptidase 9	Protein Coding	22.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
32	BCL2L1	BCL2 Like 1	Protein Coding	21.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
33	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	21.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
34	BCL2	BCL2 Apoptosis Regulator	Protein Coding	21.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
35	ZG16B	Zymogen Granule Protein 16B	Protein Coding	21.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)
36	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	21.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
37	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	21.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
38	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	21.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
39	MMP2	Matrix Metallopeptidase 2	Protein Coding	21.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
40	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	21.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
41	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	21.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
42	SMAD2	SMAD Family Member 2	Protein Coding	21.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
43	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	21.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
44	FGF2	Fibroblast Growth Factor 2	Protein Coding	21.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
45	CDK4	Cyclin Dependent Kinase 4	Protein Coding	21.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
46	MDM2	MDM2 Proto-Oncogene	Protein Coding	21.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
47	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	21.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
48	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	21.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
49	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	20.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
50	IGF1	Insulin Like Growth Factor 1	Protein Coding	20.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)

Sources

Variations for Pancreatic Adenocarcinoma

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

⁵ (show top 50) (show all 668)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	POLE	NM_006231.4(POLE):c.857C>A (p.Pro286His)	SNV	Likely Pathogenic	376502	rs1057519943	GRCh37: 12:133253184-133253184 GRCh38: 12:132676598-132676598
2	POLE	NM_006231.4(POLE):c.856C>T (p.Pro286Ser)	SNV	Likely Pathogenic	376501	rs1057519944	GRCh37: 12:133253185-133253185 GRCh38: 12:132676599-132676599
3	RXRA	NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr)	SNV	Likely Pathogenic	376529	rs1057519958	GRCh37: 9:137328351-137328351 GRCh38: 9:134436505-134436505
4	RXRA	NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe)	SNV	Likely Pathogenic	376528	rs1057519958	GRCh37: 9:137328351-137328351 GRCh38: 9:134436505-134436505
5	U2AF1	NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe)	SNV	Likely Pathogenic	376025	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
6	PIK3CA	NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)	SNV	Likely Pathogenic	376486	rs1057519937	GRCh37: 3:178952073-178952073 GRCh38: 3:179234285-179234285
7	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>C (p.Gln61Pro)	SNV	Likely Pathogenic	376322	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
8	PIK3CA	NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu)	SNV	Likely Pathogenic	376487	rs1057519936	GRCh37: 3:178952072-178952072 GRCh38: 3:179234284-179234284
9	HRAS, LRRC56	NM_005343.4(HRAS):c.38G>T (p.Gly13Val)	SNV	Likely Pathogenic	180848	rs104894226	GRCh37: 11:534285-534285 GRCh38: 11:534285-534285
10	CTNNB1	NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala)	SNV	Likely Pathogenic	17580	rs121913412	GRCh37: 3:41266124-41266124 GRCh38: 3:41224633-41224633
11	HRAS, LRRC56	NM_005343.4(HRAS):c.181C>G (p.Gln61Glu)	SNV	Likely Pathogenic	376444	rs28933406	GRCh37: 11:533875-533875 GRCh38: 11:533875-533875
12	PIK3CA	NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val)	SNV	Likely Pathogenic	376485	rs1057519936	GRCh37: 3:178952072-178952072 GRCh38: 3:179234284-179234284
13	MAP2K2	NM_030662.4(MAP2K2):c.169T>G (p.Phe57Val)	SNV	Likely Pathogenic	8273	rs121434498	GRCh37: 19:4117551-4117551 GRCh38: 19:4117553-4117553
14	CDKN2A	NM_000077.5(CDKN2A):c.247C>G (p.His83Asp)	SNV	Likely Pathogenic	376380	rs121913385	GRCh37: 9:21971111-21971111 GRCh38: 9:21971112-21971112
15	HRAS, LRRC56	NM_005343.4(HRAS):c.38G>C (p.Gly13Ala)	SNV	Likely Pathogenic	376443	rs104894226	GRCh37: 11:534285-534285 GRCh38: 11:534285-534285
16	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)	SNV	Likely Pathogenic	376033	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
17	MAP2K2	NM_030662.4(MAP2K2):c.171T>G (p.Phe57Leu)	SNV	Likely Pathogenic	376449	rs1057519910	GRCh37: 19:4117549-4117549 GRCh38: 19:4117551-4117551
18	PIK3CA	NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)	SNV	Likely Pathogenic	13659	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
19	PIK3CA	NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)	SNV	Likely Pathogenic	13656	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
20	MED12	NM_005120.3(MED12):c.3670C>G (p.Leu1224Val)	SNV	Likely Pathogenic	376452	rs1057519912	GRCh37: X:70349258-70349258 GRCh38: X:71129408-71129408
21	CTNNB1	NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn)	SNV	Likely Pathogenic	376394	rs121913413	GRCh37: 3:41266125-41266125 GRCh38: 3:41224634-41224634
22	U2AF1	NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr)	SNV	Likely Pathogenic	376026	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
23	PIK3CA	NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)	SNV	Likely Pathogenic	375896	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
24	CDKN2A	NM_000077.5(CDKN2A):c.150G>T (p.Gln50His)	SNV	Likely Pathogenic	376384	rs1057519882	GRCh37: 9:21974677-21974677 GRCh38: 9:21974678-21974678
25	ERBB2	NM_004448.4(ERBB2):c.2524G>A (p.Val842Ile)	SNV	Likely Pathogenic	375994	rs1057519738	GRCh37: 17:37881332-37881332 GRCh38: 17:39725079-39725079
26	KRAS	NM_004985.5(KRAS):c.183A>T (p.Gln61His)	SNV	Likely Pathogenic	45117	rs17851045	GRCh37: 12:25380275-25380275 GRCh38: 12:25227341-25227341
27	MED12	NM_005120.3(MED12):c.3670C>T (p.Leu1224Phe)	SNV	Likely Pathogenic	376451	rs1057519912	GRCh37: X:70349258-70349258 GRCh38: X:71129408-71129408
28	PIK3CA	NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)	SNV	Likely Pathogenic	13653	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
29	CTNNB1	NM_001904.4(CTNNB1):c.97T>A (p.Ser33Thr)	SNV	Likely Pathogenic	376393	rs1057519886	GRCh37: 3:41266100-41266100 GRCh38: 3:41224609-41224609
30	CTNNB1	NM_001904.4(CTNNB1):c.98C>T (p.Ser33Phe)	SNV	Likely Pathogenic	17583	rs121913400	GRCh37: 3:41266101-41266101 GRCh38: 3:41224610-41224610
31	PIK3CA	NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)	SNV	Likely Pathogenic	217293	rs121913275	GRCh37: 3:178936093-178936093 GRCh38: 3:179218305-179218305
32	CTNNB1	NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr)	SNV	Likely Pathogenic	17577	rs121913400	GRCh37: 3:41266101-41266101 GRCh38: 3:41224610-41224610
33	SF3B2	NM_006842.3(SF3B2):c.2099A>G (p.Glu700Gly)	SNV	Likely Pathogenic	376533	rs1057519960	GRCh37: 11:65830884-65830884 GRCh38: 11:66063413-66063413
34	CTNNB1	NM_001904.4(CTNNB1):c.98C>G (p.Ser33Cys)	SNV	Likely Pathogenic	376231	rs121913400	GRCh37: 3:41266101-41266101 GRCh38: 3:41224610-41224610
35	MYCNOS, MYCN	NM_005378.6(MYCN):c.131C>T (p.Pro44Leu)	SNV	Likely Pathogenic	376460	rs1057519919	GRCh37: 2:16082317-16082317 GRCh38: 2:15942195-15942195
36	PIK3CA	NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln)	SNV	Likely Pathogenic	376481	rs1057519932	GRCh37: 3:178952086-178952086 GRCh38: 3:179234298-179234298
37	CTNNB1	NM_001904.4(CTNNB1):c.97T>G (p.Ser33Ala)	SNV	Likely Pathogenic	376392	rs1057519886	GRCh37: 3:41266100-41266100 GRCh38: 3:41224609-41224609
38	CTNNB1	NM_001904.4(CTNNB1):c.97T>C (p.Ser33Pro)	SNV	Likely Pathogenic	376391	rs1057519886	GRCh37: 3:41266100-41266100 GRCh38: 3:41224609-41224609
39	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Likely Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
40	PIK3CA	NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp)	SNV	Likely Pathogenic	156446	rs587777790	GRCh37: 3:178917478-178917478 GRCh38: 3:179199690-179199690
41	PIK3CA	NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)	SNV	Likely Pathogenic	39705	rs121913281	GRCh37: 3:178952084-178952084 GRCh38: 3:179234296-179234296
42	PIK3CA	NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile)	SNV	Likely Pathogenic	179173	rs121913283	GRCh37: 3:178952074-178952074 GRCh38: 3:179234286-179234286
43	TP53	NM_000546.6(TP53):c.518T>G (p.Val173Gly)	SNV	Likely Pathogenic	376016	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
44	TP53	NM_000546.6(TP53):c.706T>G (p.Tyr236Asp)	SNV	Likely Pathogenic	142183	rs587782289	GRCh37: 17:7577575-7577575 GRCh38: 17:7674257-7674257
45	TP53	NM_000546.6(TP53):c.452C>G (p.Pro151Arg)	SNV	Likely Pathogenic	376640	rs1057520000	GRCh37: 17:7578478-7578478 GRCh38: 17:7675160-7675160
46	TP53	NM_000546.6(TP53):c.613T>G (p.Tyr205Asp)	SNV	Likely Pathogenic	376686	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
47	TP53	NM_000546.6(TP53):c.452C>A (p.Pro151His)	SNV	Likely Pathogenic	376639	rs1057520000	GRCh37: 17:7578478-7578478 GRCh38: 17:7675160-7675160
48	TP53	NM_000546.6(TP53):c.577C>A (p.His193Asn)	SNV	Likely Pathogenic	376614	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
49	TP53	NM_000546.6(TP53):c.824G>T (p.Cys275Phe)	SNV	Likely Pathogenic	376582	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796
50	TP53	NM_000546.6(TP53):c.644G>A (p.Ser215Asn)	SNV	Likely Pathogenic	376662	rs587782177	GRCh37: 17:7578205-7578205 GRCh38: 17:7674887-7674887

Sources

Expression for Pancreatic Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.

Sources

Pathways for Pancreatic Adenocarcinoma

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 122)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.91	CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.87	TP53 SMAD4 PIK3CA MUC4 MAP2K2 KRAS
3	Signal Transduction ⁶⁶	13.82	CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.78	CDKN2A EGFR ERBB2 GNAS HRAS KRAS
5	Nervous system development ⁶⁶ Show member pathways Axon guidance ⁶⁶ Developmental Biology ⁶⁶	13.78	CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.71	EGFR ERBB2 GNAS HRAS KRAS MAP2K2
7	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.64	SMAD4 MAP2K2 KRAS HRAS GNAS ERBB2
8	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.62	TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
9	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.55	TP53 PIK3CA MAP2K2 KRAS HRAS GNAS
10	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.48	CTNNB1 EGFR GNAS HRAS KRAS MAP2K2
11	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.47	CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
12	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.36	CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
13	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.15	EGFR GNAS HRAS KRAS MAP2K2 TP53
14	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.04	TP53 PIK3CA MAP2K2 KRAS HRAS EGFR
15	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13.01	TP53 PIK3CA MAP2K2 HRAS EGFR CDKN2A
16	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.98	PIK3CA MAP2K2 KRAS HRAS GNAS CTNNB1
17	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.96	PIK3CA MAP2K2 KRAS HRAS GNAS ERBB2
18	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.94	TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
19	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.92	PIK3CA MAP2K2 KRAS HRAS EGFR
20	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.91	PIK3CA MAP2K2 KRAS HRAS CTNNB1
21	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.91	PIK3CA MYCN MAP2K2 KRAS HRAS ERBB2
22	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.87	TP53 MAP2K2 KRAS HRAS GNAS CTNNB1
23	DREAM Repression and Dynorphin Expression ⁶⁴ Show member pathways Arrhythmogenic right ventricular cardiomyopathy ⁷⁴ BMP Pathway ⁶⁴ Calpain Protease Regulates Cellular Mechanics ⁶⁴ Caspase Cascade ⁶⁴ nNOS Signaling in Skeletal Muscle ⁶⁴ Presynaptic depolarization and calcium channel opening ⁶⁶ TOB in Osteoblast Signaling ⁶⁴	12.85	SMAD4 KRAS HRAS EGFR CTNNB1
24	G-AlphaQ Signaling ⁶⁴ Show member pathways G-AlphaI Signaling ⁶⁴ PAR4-mediated thrombin signaling events ⁶¹ Thrombin Signaling ⁶⁴	12.77	MAP2K2 KRAS HRAS GNAS EGFR
25	G-protein signaling G-Protein alpha-i signaling cascades ²² Show member pathways Development Beta-adrenergic receptors regulation of ERK ²² G-protein signaling G-Protein alpha-s signaling cascades ²² G-protein signaling G-Protein beta/gamma signaling cascades ²² Signaling in Gap Junctions ⁶⁴	12.77	MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
26	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.76	TP53 MAP2K2 KRAS HRAS EGFR
27	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.76	MAP2K2 KRAS HRAS GNAS EGFR CDKN2A
28	Malignant pleural mesothelioma ⁷⁴	12.76	TP53 PIK3CA MAP2K2 HRAS EGFR CTNNB1
29	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.73	TP53 PIK3CA MAP2K2 KRAS HRAS EGFR
30	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.67	TP53 PIK3CA KRAS HRAS ERBB2 EGFR
31	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.56	TP53 PIK3CA MAP2K2 HRAS ERBB2 CTNNB1
32	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.54	EGFR HRAS KRAS MAP2K2 PIK3CA
33	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.52	CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
34	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.52	TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
35	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.51	PIK3CA MAP2K2 KRAS HRAS EGFR
36	MAPK signaling pathway ⁷⁴	12.5	TP53 MAP2K2 KRAS HRAS EGFR
37	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.5	PIK3CA MAP2K2 KRAS HRAS CTNNB1
38	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.49	PIK3CA MAP2K2 KRAS HRAS
39	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.49	TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
40	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.47	PIK3CA MAP2K2 KRAS HRAS ERBB2 EGFR
41	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.42	TP53 PIK3CA MAP2K2 HRAS GNAS
42	Development A3 receptor signaling ²² Show member pathways Development A1 receptor signaling ²² G-protein signaling G-Protein alpha-q signaling cascades ²²	12.41	PIK3CA MAP2K2 HRAS CTNNB1
43	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.41	CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
44	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.4	PIK3CA MAP2K2 KRAS HRAS
45	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.4	PIK3CA KRAS HRAS CTNNB1
46	Focal adhesion ⁷⁴	12.4	PIK3CA HRAS ERBB2 EGFR CTNNB1
47	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.39	RXRA PIK3CA MAP2K2 HRAS GNAS ERBB2
48	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.35	TP53 PIK3CA MAP2K2 HRAS
49	Ras signaling ⁷⁴	12.35	PIK3CA MAP2K2 KRAS HRAS EGFR
50	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.35	EGFR ERBB2 HRAS KRAS PIK3CA

Sources

GO Terms for Pancreatic Adenocarcinoma

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	perinuclear region of cytoplasm	GO:0048471	9.44	PIK3CA MAP2K2 HRAS GNAS ERBB2 EGFR

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.39	CDKN2A CTNNB1 EGFR HRAS MED12 MYCN
2	positive regulation of DNA-templated transcription	GO:0045893	10.25	TP53 SMAD4 RXRA MYCN MED12 MAP2K2
3	negative regulation of gene expression	GO:0010629	10.18	TP53 PIK3CA MYCN HRAS CTNNB1
4	heart development	GO:0007507	10.08	TP53 MED12 MAP2K2 ERBB2 CTNNB1
5	MAPK cascade	GO:0000165	10.07	CTNNB1 EGFR HRAS KRAS MAP2K2
6	Ras protein signal transduction	GO:0007265	10.01	TP53 KRAS HRAS CDKN2A
7	positive regulation of gene expression	GO:0010628	9.93	TP53 MYCN MAP2K2 KRAS HRAS ERBB2
8	cell population proliferation	GO:0008283	9.91	TP53 SMAD4 KRAS EGFR CTNNB1
9	embryonic organ development	GO:0048568	9.73	CTNNB1 MED12 POLE TP53
10	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.69	ERBB2 CDKN2A
11	hair follicle placode formation	GO:0060789	9.67	GNAS CTNNB1
12	regulation of cell population proliferation	GO:0042127	9.5	TP53 SMAD4 HRAS ERBB2 EGFR CTNNB1
13	positive regulation of miRNA maturation	GO:1903800	9.02	TP53 MYCN MAP2K2 EGFR

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	10.1	TP53 SMAD4 POLE MED12 EGFR CTNNB1
2	nucleotide binding	GO:0000166	9.91	POLE PIK3CA MAP2K2 KRAS HRAS GNAS
3	protein phosphatase binding	GO:0019903	9.56	TP53 ERBB2 EGFR CTNNB1
4	disordered domain specific binding	GO:0097718	9.55	TP53 CTNNB1 CDKN2A
5	protein serine/threonine kinase activator activity	GO:0043539	9.02	PIK3CA MAP2K2 KRAS HRAS